Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Income from Non-Controlling Interests (2023)

Ironwood Pharmaceuticals (IRWD) has disclosed Income from Non-Controlling Interests for 2 consecutive years, with -$658000.0 as the latest value for Q4 2023.

  • Quarterly Income from Non-Controlling Interests changed N/A to -$658000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$29.3 million through Dec 2023, changed N/A year-over-year, with the annual reading at -$29.3 million for FY2023, N/A changed from the prior year.
  • Income from Non-Controlling Interests hit -$658000.0 in Q4 2023 for Ironwood Pharmaceuticals, up from -$1.4 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of -$658000.0 in Q4 2023 to a low of -$27.3 million in Q2 2023.